A planned comparison
Verma and colleagues pooled two randomized semaglutide trials in obesity-related heart failure with preserved ejection fraction. Of 1,145 participants, 570 were women. The analysis compared changes over 52 weeks by sex.
Weight and symptoms diverged
Compared with placebo, weight reduction was greater in women than men: 9.6 versus 7.2 percentage points. Yet the improvement in a heart-failure symptom and limitation score was almost identical: 7.6 versus 7.5 points. The analysis supported a sex difference for weight change, but not for that symptom outcome.
Ask an outcome-specific question
S7’s reading lesson is to ask which result differs, rather than saying a medicine simply works better for women. A subgroup analysis cannot establish identical responses in every individual. These findings concern a defined heart-failure population, not healthy adults. The full indexed abstract was reviewed; publisher full text was unavailable. This is not treatment advice or proof of research-vial equivalence.